{"schema_version":"secwatch.filing_event.v1","accession":"0000899923-24-000054","form_type":"8-K","ticker":"MYGN","cik":"0000899923","company_name":"MYRIAD GENETICS INC","filed_at":"2024-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:11.330680+00:00","generated_at":"2026-05-30T04:11:22.657422+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Myriad Genetics Q3 revenue +11% to $213M, adj EPS $0.06; UNH to drop GeneSight coverage Jan 2025","bullets":["Q3 revenue $213M (+11% YoY); GAAP net loss $22.1M improved from $61.3M loss; adj EBITDA $14.1M vs $1.4M.","GAAP EPS -$0.24 vs -$0.75; adj EPS $0.06 vs -$0.03.","FY2024 guidance raised: revenue $837-843M, adj EPS $0.12-0.14.","UnitedHealthcare to stop covering GeneSight for commercial plans Jan 1, 2025; $10M Q3 / $40M TTM revenue at risk from UNH commercial.","GeneSight revenue +34% YoY to $47.7M; total test volumes +6% to 376K."],"urls":{"canonical":"https://secwatch.observer/filing/0000899923-24-000054","json":"https://secwatch.observer/filing/0000899923-24-000054.json","markdown":"https://secwatch.observer/filing/0000899923-24-000054.md","text":"https://secwatch.observer/filing/0000899923-24-000054.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/899923/000089992324000054/0000899923-24-000054-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/899923/000089992324000054/mygn-20241107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T04:11:22.657422+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}